| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Stefania Butini, Sandra Gemma, Giuseppe Campiani, Silvia Franceschini, Francesco Trotta, Marianna Borriello, Nicoletta Ceres, Sindu Ros, Salvatore Sanna Coccone, Matteo Bernetti, Meri De Angelis, Margherita Brindisi, Vito Nacci, Isabella Fiorini, Ettore Novellino, Alfredo Cagnotto, Tiziana Mennini, Karin Sandager-Nielsen, Jesper Tobias Andreasen, Jorgen Scheel-Kruger, Jens D Mikkelsen, Caterina Fattoruss. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. Journal of medicinal chemistry. vol 52. issue 1. 2009-02-06. PMID:19072656. |
discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine d3 and serotonin 5-ht1a and 5-ht2a receptors: design, synthesis, and effects on behavior. |
2009-02-06 |
2023-08-12 |
Not clear |
| Andrea Gogos, Mirjana Bogeski, Maarten van den Buus. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology. Behavioural pharmacology. vol 19. issue 5-6. 2008-12-31. PMID:18690109. |
in balb/c mice, the effect of 8-oh-dpat was blocked by the typical antipsychotic and dopamine d2 receptor antagonist, haloperidol and the third generation antipsychotic, aripiprazole, which has activity at both 5-ht1a and dopamine d2 receptors. |
2008-12-31 |
2023-08-12 |
mouse |
| K Wedzony, A Chocyk, M Maćkowia. A search for colocalization of serotonin 5-HT2A and 5-HT1A receptors in the rat medial prefrontal and entorhinal cortices--immunohistochemical studies. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. vol 59. issue 2. 2008-11-25. PMID:18622042. |
recently developed antipsychotic drugs ameliorating the negative symptoms of schizophrenia act not only on dopamine d2 receptors but also on serotonin 2a (5-ht2a) and 1a (5-ht1a) receptors in specific regions of the cerebral cortex. |
2008-11-25 |
2023-08-12 |
rat |
| Zofia Rogó. Effect of repeated co-treatment with imipramine and metyrapone on the behavioral reactivity of the central serotonin, dopamine and alpha 1-adrenergic systems in rats. Pharmacological reports : PR. vol 59. issue 5. 2008-11-18. PMID:18048960. |
the aim of present study was to examine the effect of repeated co-treatment with imipramine and metyrapone on the development of adaptive changes in the function of central serotonin 5-ht1a and 5-ht2a, dopamine d2/3 and alpha 1-adrenergic receptors in rats. |
2008-11-18 |
2023-08-12 |
rat |
| Zofia Rogó. Effect of repeated co-treatment with imipramine and metyrapone on the behavioral reactivity of the central serotonin, dopamine and alpha 1-adrenergic systems in rats. Pharmacological reports : PR. vol 59. issue 5. 2008-11-18. PMID:18048960. |
the obtained results showed that repeated co-treatment with imipramine (5 or 10 mg/kg) and metyrapone (50 mg/kg) (twice daily for 14 days) either induced more potent inhibition of the behavioral syndrome evoked by 5-ht1a and 5-ht2a receptor agonists (8-oh-dpat and (+/-)doi, respectively), or did no change the action of amphetamine and wuinpirole (a dopamine d2/3 agonist) or phenylephrine (an alpha 1-adrenergic agonist) compared to treatment with either drug alone. |
2008-11-18 |
2023-08-12 |
rat |
| Marie-Bernadette Assié, Elisabeth Carilla-Durand, Laurent Bardin, Mireille Maraval, Monique Aliaga, Nathalie Malfètes, Michèle Barbara, Adrian Newman-Tancred. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. European journal of pharmacology. vol 592. issue 1-3. 2008-10-24. PMID:18640111. |
several novel antipsychotics activate serotonin 5-ht1a receptors as well as antagonising dopamine d2/3 receptors. |
2008-10-24 |
2023-08-12 |
rat |
| Marie-Bernadette Assié, Elisabeth Carilla-Durand, Laurent Bardin, Mireille Maraval, Monique Aliaga, Nathalie Malfètes, Michèle Barbara, Adrian Newman-Tancred. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. European journal of pharmacology. vol 592. issue 1-3. 2008-10-24. PMID:18640111. |
here, we compared the influence on plasma glucose and corticosterone of acute treatments with 'new generation' antipsychotics which target dopamine d2/3 receptors and 5-ht1a receptors, with that of atypical antipsychotics, and with haloperidol. |
2008-10-24 |
2023-08-12 |
rat |
| Liesbeth A Bruins Slot, Laurent Bardin, Agnès L Auclair, Ronan Depoortere, Adrian Newman-Tancred. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behavioural pharmacology. vol 19. issue 2. 2008-06-17. PMID:18332679. |
inhibition of marble burying behavior may result from the interplay of several receptor systems, including 5-ht2 receptor blockade, dopamine d2 partial agonism and serotonin 5-ht1a agonism. |
2008-06-17 |
2023-08-12 |
mouse |
| Peter Heusler, Adrian Newman-Tancredi, Timothé Loock, Didier Cussa. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. European journal of pharmacology. vol 581. issue 1-2. 2008-05-23. PMID:18190908. |
antipsychotics differ in their ability to internalise human dopamine d2s and human serotonin 5-ht1a receptors in hek293 cells. |
2008-05-23 |
2023-08-12 |
human |
| Pia Weikop, Jan Kehr, Jørgen Scheel-Krüge. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors. Journal of psychopharmacology (Oxford, England). vol 21. issue 8. 2008-01-29. PMID:17984160. |
reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-ht1a receptors. |
2008-01-29 |
2023-08-12 |
rat |
| Takeo Ishiyama, Kumiko Tokuda, Tadashi Ishibashi, Akira Ito, Satoko Toma, Yukihiro Ohn. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. European journal of pharmacology. vol 572. issue 2-3. 2008-01-14. PMID:17662268. |
lurasidone (sm-13496) is a novel atypical antipsychotic with high affinities to dopamine d2, serotonin 5-ht7, 5-ht2a, 5-ht1a receptors and alpha2c adrenoceptor. |
2008-01-14 |
2023-08-12 |
rat |
| Steven M Southwick, Meena Vythilingam, Dennis S Charne. The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annual review of clinical psychology. vol 1. 2007-09-21. PMID:17716089. |
neurobiological factors that are discussed and contrasted include serotonin, the 5-ht1a receptor, polymorphisms of the 5-ht transporter gene, norepinephrine, alpha-2 adrenergic receptors, neuropeptide y, polymorphisms of the alpha-2 adrenergic gene, dopamine, corticotropin-releasing hormone (crh), dehydroepiandrosterone (dhea), cortisol, and crh receptors. |
2007-09-21 |
2023-08-12 |
Not clear |
| Agnès L Auclair, Alexandra Galinier, Joël Besnard, Adrian Newman-Tancredi, Ronan Depoortèr. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology. vol 193. issue 1. 2007-09-06. PMID:17393144. |
putative antipsychotics with pronounced agonism at serotonin 5-ht1a and partial agonist activity at dopamine d2 receptors disrupt basal ppi of the startle reflex in rats. |
2007-09-06 |
2023-08-12 |
rat |
| Manolo Carta, Thomas Carlsson, Deniz Kirik, Anders Björklun. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain : a journal of neurology. vol 130. issue Pt 7. 2007-07-24. PMID:17452372. |
removal of the serotonin afferents, or dampening of serotonin neuron activity by 5-ht1a and 5-ht1b agonist drugs, resulted in a near-complete block of the l-dopa-induced dyskinesias, suggesting that dysregulated dopamine release from serotonin terminals is the prime trigger of dyskinesia in the rat parkinson's disease model. |
2007-07-24 |
2023-08-12 |
rat |
| Manolo Carta, Thomas Carlsson, Deniz Kirik, Anders Björklun. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain : a journal of neurology. vol 130. issue Pt 7. 2007-07-24. PMID:17452372. |
the potent synergistic effect of low doses of 5-ht1a and 5-ht1b agonists to suppress dyskinesia, without affecting the anti-parkinsonian effect of l-dopa in presence of spared dopamine terminals, suggests an early use of these drugs to counteract the development of dyskinesia in parkinson's disease patients. |
2007-07-24 |
2023-08-12 |
rat |
| Maiko Sato, Yukio Ago, Ken Koda, Shigeo Nakamura, Toshiyuki Kawasaki, Akemichi Baba, Toshio Matsud. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. European journal of pharmacology. vol 559. issue 2-3. 2007-05-09. PMID:17258195. |
on the other hand, local application of risperidone (3 and 10 microm), the 5-ht1a receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (1 and 10 microm), and the dopamine d4 receptor antagonist 3-(4-(4-iodophenyl)piperazine-1-yl)methyl-1h-pyrrolo[2,3-b]pyridine (1 and 10 microm) into the cortex did not affect acetylcholine release in the prefrontal cortex. |
2007-05-09 |
2023-08-12 |
rat |
| Laurent Bardin, Agnès Auclair, Mark S Kleven, Eric P M Prinssen, Wouter Koek, Adrian Newman-Tancredi, Ronan Depoortèr. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behavioural pharmacology. vol 18. issue 2. 2007-05-08. PMID:17351418. |
pharmacological profiles in rats of novel antipsychotics with combined dopamine d2/serotonin 5-ht1a activity: comparison with typical and atypical conventional antipsychotics. |
2007-05-08 |
2023-08-12 |
rat |
| Laurent Bardin, Agnès Auclair, Mark S Kleven, Eric P M Prinssen, Wouter Koek, Adrian Newman-Tancredi, Ronan Depoortèr. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behavioural pharmacology. vol 18. issue 2. 2007-05-08. PMID:17351418. |
combining antagonist/partial agonist activity at dopamine d2 and agonist activity at serotonin 5-ht1a receptors is one of the approaches that has recently been chosen to develop new generation antipsychotics, including bifeprunox, ssr181507 and slv313. |
2007-05-08 |
2023-08-12 |
rat |
| Laurent Bardin, Agnès Auclair, Mark S Kleven, Eric P M Prinssen, Wouter Koek, Adrian Newman-Tancredi, Ronan Depoortèr. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behavioural pharmacology. vol 18. issue 2. 2007-05-08. PMID:17351418. |
potency against ketamine-induced hyperlocomotion was independent of affinity at dopamine d2 or 5-ht1a receptors. |
2007-05-08 |
2023-08-12 |
rat |
| Stephane Cuisiat, Nathalie Bourdiol, Vincent Lacharme, Adrian Newman-Tancredi, Francis Colpaert, Bernard Vache. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. Journal of medicinal chemistry. vol 50. issue 4. 2007-03-27. PMID:17300168. |
we report the discovery and the synthesis of novel, potential antipsychotic compounds combining potent dopamine d2 receptor antagonist and serotonin 5-ht1a receptor agonist properties in the same molecule. |
2007-03-27 |
2023-08-12 |
rat |